Medische Oncologie Nummer 2, pp. 35-37
jun 2004, jaargang 7
Medische Oncologie Nr. 2, pp. 35-37
jun 2004, jr. 7
BOM

Trastuzumab bij het mammacarcinoom

Lees online

Een combinatie van trastuzumab met een taxoid moet op basis van de aangetoonde hogere effectiviteit als de combinatie van eerste keuze worden beschouwd bij patiënten met een (3+) positieve Her2/neu-receptor in het tumorweefsel.

Referenties

  1. Baselga J et al. ‘Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer’. Semin Oncol 1999;26:78-83. 
  2. Cobleigh MA et al. ‘Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease’. J Clin Oncol 1999;17: 2639-48.
  3. Vogel CL et al. ‘Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer’. J Clin Oncol 2002;20:719-26.
  4. Seidman AD et al. ‘Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification’. J Clin Oncol 2001;19:2587-95.
  5. Burstein HJ et al. ‘Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study’. J Clin Oncol 2003;21:46-53.
  6. Burstein HJ et al. ‘Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer’. J Clin Oncol 2001;19:2722-30.
  7. Esteva FJ et al. ‘Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer’. J Clin Oncol 2002; 20:1800-8
  8. Pegram MD et al. ‘Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antip185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment’. J Clin Oncol 1998;16:2659-71.
  9. Loesch D et al. ‘Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer’. J Clin Oncol 2002;20:3857-64.
  10. Gori S et al. ‘Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2- overexpressing metastatic breast cancer’. Br J Cancer 2004;90:36-40.
  11. Tedesco KL et al. ‘Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridizationpositive metastatic
    breast cancer: a multiinstitutional phase II trial’. J Clin Oncol 2004;22:1071-7.
  12. Slamon DJ et al. ‘Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2’. N Engl J Med
    2001;15:783-92.
BOM

Trastuzumab bij het mammacarcinoom

Lees online

Een combinatie van trastuzumab met een taxoid moet op basis van de aangetoonde hogere effectiviteit als de combinatie van eerste keuze worden beschouwd bij patiënten met een (3+) positieve Her2/neu-receptor in het tumorweefsel.

Referenties

  1. Baselga J et al. ‘Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer’. Semin Oncol 1999;26:78-83. 
  2. Cobleigh MA et al. ‘Multinational study of the efficacy and safety of humanized anti- HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease’. J Clin Oncol 1999;17: 2639-48.
  3. Vogel CL et al. ‘Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer’. J Clin Oncol 2002;20:719-26.
  4. Seidman AD et al. ‘Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification’. J Clin Oncol 2001;19:2587-95.
  5. Burstein HJ et al. ‘Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study’. J Clin Oncol 2003;21:46-53.
  6. Burstein HJ et al. ‘Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer’. J Clin Oncol 2001;19:2722-30.
  7. Esteva FJ et al. ‘Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer’. J Clin Oncol 2002; 20:1800-8
  8. Pegram MD et al. ‘Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antip185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment’. J Clin Oncol 1998;16:2659-71.
  9. Loesch D et al. ‘Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer’. J Clin Oncol 2002;20:3857-64.
  10. Gori S et al. ‘Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2- overexpressing metastatic breast cancer’. Br J Cancer 2004;90:36-40.
  11. Tedesco KL et al. ‘Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridizationpositive metastatic
    breast cancer: a multiinstitutional phase II trial’. J Clin Oncol 2004;22:1071-7.
  12. Slamon DJ et al. ‘Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2’. N Engl J Med
    2001;15:783-92.
Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 juni 2004
E-pubdatum
17 juni 2004
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 juni 2004
E-pubdatum
17 juni 2004
ISSN print
1388-2295
ISSN online
2405-4763